Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women’s health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee’s Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson’s, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson’s Baby, Johnson’s Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Strategic Overhaul | Explore Kenvue's ambitious "Extraordinary Powers" strategy, aimed at simplifying operations and driving innovation across its diverse product portfolio |
Market Challenges | Delve into Kenvue's response to declining organic sales and regulatory scrutiny, including leadership changes and a comprehensive strategic review |
Brand Powe | Learn how Kenvue leverages its iconic brands like Tylenol and Neutrogena to maintain market leadership despite fierce competition in the consumer health secto |
Financial Outlook | Analyst price targets range from $22 to $29, reflecting varied perspectives on Kenvue's potential for operational improvements and long-term value creation |
Metrics to compare | KVUE | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipKVUEPeersSector | |
|---|---|---|---|---|
P/E Ratio | 23.0x | 22.1x | 12.2x | |
PEG Ratio | 0.56 | −1.55 | 0.03 | |
Price/Book | 3.1x | 4.0x | 1.5x | |
Price / LTM Sales | 2.2x | 2.2x | 0.9x | |
Upside (Analyst Target) | 8.1% | 9.3% | 20.5% | |
Fair Value Upside | Unlock | 18.7% | 11.1% | Unlock |